Vertex Pharmaceuticals Inc (VRTX)vsVistaGen Therapeutics Inc (VTGN)
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
VTGN
VistaGen Therapeutics Inc
$0.61
-0.97%
HEALTHCARE · Cap: $24.42M
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 1520977% more annual revenue ($12.00B vs $789,000). VRTX leads profitability with a 32.9% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 66/100 (B-).
VRTX
Strong Buy66
out of 100
Grade: B-
VTGN
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Intrinsic value data unavailable for VTGN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Reasonable price relative to book value
Revenue surging 29.5% year-over-year
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -101.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bull Case : VTGN
The strongest argument for VTGN centers on Price/Book, Revenue Growth. Revenue growth of 29.5% demonstrates continued momentum.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Bear Case : VTGN
The primary concerns for VTGN are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
VRTX profiles as a mature stock while VTGN is a growth play — different risk/reward profiles.
VTGN carries more volatility with a beta of 0.33 — expect wider price swings.
VTGN is growing revenue faster at 29.5% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 34/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
VistaGen Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing and commercializing several drugs with the potential to treat anxiety, depression, and other central nervous system (CNS) disorders. The company is headquartered in South San Francisco, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?